SIGMA

A small molecule under development as a treatment for dry age-related macular degeneration (dry AMD), both early-stage disease and late-stage (geographic atrophy).

Both eyedropper and oral dosage forms are under development.

Currently there are no approved treatments for early-stage disease and Filamon sees its current SIGMA drug candidates as a potential treatments able to stop progression of a disease estimated to affect 200 million people globally.